Covid-19 Living Data

Study registration: *
Publication Puranik A, medRxiv, 2021
Dates: 2021-07-01 to 2021-07-30
Funding: No specific funding (No external funding was received for this study.)
Conflict of interest: Yes (AP, PJL, ES, MJN, JC, AJV, and VS are employees of nference and have financial interests in the company. nference is collaborating with Moderna, Pfizer, Janssen, and other bio-pharmaceutical companies on data science initiatives unrelated to this study. These collaborations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. JCO receives personal fees from Elsevier and Bates College, and receives small grants from nference, Inc, outside the submitted work. ADB is supported by grants from NIAID (grants AI110173 and AI120698), Amfar (#109593), and Mayo Clinic (HH Shieck Khalifa Bib Zayed Al-Nahyan Named Professorship of Infectious Diseases). ADB is a paid consultant for Abbvie, Gilead, Freedom Tunnel, Pinetree therapeutics Primmune, Immunome and Flambeau Diagnostics, is a paid member of the DSMB for Corvus Pharmaceuticals, Equilium, and Excision Biotherapeutics, has received fees for speaking for Reach MD and Medscape, owns equity for scientific advisory work in Zentalis and nference, and is founder and President of Splissen Therapeutics. MDS received grant funding from Pfizer via Duke University for a vaccine side effect registry. JH, JCO, AV, MDS and ADB are employees of the Mayo Clinic. The Mayo Clinic may stand to gain financially from the successful outcome of the research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.)

Methods
Methods	Study design:Cohort Description of participants: Adults who underwent SARS-CoV-2 polymerase chain reaction (PCR) testing in multiple centers in USA Inclusion criteria: Age greater than or equal to 18 years received at least one dose of BNT162b2 or mRNA-1273 after December 1, 2020 and on or before July 29, 2021 did not have any positive SARS-CoV-2 PCR tests prior to their first vaccine dose did not receive a mismatched series of COVID-19 vaccines (e.g., did not receive doses from more than one manufacturer). Exclusion criteria: Positive SARS-CoV-2 PCR tests prior to first vaccine dose received a mismatched series of COVID-19 vaccines (e.g., doses from more than one manufacturer). Follow-up duration (months): 1
Vaccines:	2 doses of mRNA-1273 2 doses of BNT162b2 2 doses of mRNA-1273
Variant description :
Variant description :	Variant name: Delta Evidence: Indirect evidence (prevalence of variant in the population: >50%)
Documents available	Protocol NR Statistical plan No Data-sharing stated: Yes, after publication Data accessibility: Correspondence to Venky Soundararajan (venky@nference.net)
General comment	There is likely to be uncontrolled confounding, and we have a concern about selection bias because the analysis is restricted to individuals who had a PCR test, and this could be influenced by both vaccination and infection (sometimes referred to as collider bias).